CGRP Forum
Send to a colleague
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Aimovig (erenumab) approved for migraine prevention in US adults

Aimovig (erenumab) is the first CGRP receptor inhibitor to be approved for migraine prevention in adults in the US. Patients will self administer Aimovig 70 mg or 140 mg once a month via the SureClick autoinjector.

Read the full report here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.